Regulatory issues

It is in the common interest of public authorities and manufacturers to make a success of reduced-risk tobacco and nicotine products that meet the expectations of existing adult smokers and vapers. It is key to work together with public health bodies, the scientific community and regulatory authorities so we can help create the best possible framework that will allow these products to reach their full potential.


In April 2014 the European Union (EU) introduced new regulatory measures on tobacco products and e-cigarettes under the Tobacco Products Directive (EU TPD). Although we understand the need to regulate e-cigarettes, we are concerned that certain regulatory requirements of the EU TPD stray beyond what is strictly necessary to ensure a high standard of consumer protection. This excessive approach not only raises the cost for consumers but also detrimentally affects manufacturers’ abilities to deliver innovative and even better products to consumers. 

FDA's New Regulations for E-Cigarettes, Cigars, and All Other Tobacco Products

In 2016 the U.S. Food and Drug Administration (FDA) extended tobacco regulations to cover e-cigarettes and other tobacco products. Some of the new provisions, in particular, data requirements and pre-market authorizations, are extremely challenging and even more stringent than the EU TPD. Despite this, our team of experts continues to prepare product submissions and JTI remains resolute that Logic will continue to be a leading player in the U.S.

World Health Organisation (WHO)

The WHO FCTC (Framework Convention on Tobacco Control) continues to prohibit or restrict e-cigarettes, even though these products do not contain tobacco. This non-binding recommendation, which was agreed behind closed doors, does not appear to be based on an objective assessment of the available scientific evidence. Furthermore, it is at odds with recent authoritative opinions1 which conclude that the use of e-cigarettes is likely to be less harmful to health than smoking.


1 Public Health England (PHE) report:
The Royal College of Physicians (RCP) report:


countries where our products are distributed


factory where we manufacture snus